GSK shares fell more than 5% after U.S. health officials narrowed their recommendation of respiratory syncytial virus vaccines to a smaller age range and more at-risk patients.
Related Posts
Chinese Developer Kaisa Makes Progress on Offshore Debt Restructuring
Chinese property developer Kaisa Group Holdings said it has made significant progress in restructuring its offshore liabilities, enabling the beleaguered company to offer billions of […]
Campari Names New CEO
The Aperol maker said it would appoint Simon Hunt as its new chief executive officer, months after Matteo Fantacchiotti resigned from the role for personal […]
Mitsubishi UFJ’s Quarterly Profit Falls on Higher Credit Costs
The Japanese financial company reported a decline in its first-quarter net profit, partly due to higher credit costs.